Evaluation of SARS-CoV-2 Antibody Levels in Pharmacists and Pharmacy Staff Following CoronaVac Vaccination
- 19 January 2024
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 20 (6) , 347-351
Abstract
The aim of this study was to determine the seropositivity rate of pharmacists and pharmacy staff after the administration of two doses of the CoronaVac-SinoVac vaccine and to assess changes in their antibody levels according to sociodemographic characteristics. This descriptive study was conducted between June 04, 2021 and September 30, 2021 in pharmacies located in Istanbul, Türkiye. The results of self-initiated immunoglobulin (Ig) G testing of the pharmacists and pharmacy staff, conducted at diagnostic laboratories contracted by the Istanbul Chamber of Pharmacists, were obtained using an online data collection tool. IgG measurements taken from 15 days up to 120 days after the two vaccine doses were included in the study. Participants were asked whether they smoked, had any chronic diseases (hypertension, chronic obstructive pulmonary disease, asthma, diabetes, etc.), or took any medications. Subgroup analyses were performed for each method used to measure antibody levels. The study included 329 pharmacists/pharmacy staff (298 pharmacists and 31 pharmacy staff). The mean age of the participants was 49.7 ± 13.7 years, and 71.4% were female. The antibody positivity of the 329 participants was 94.9% following the two doses. The positivity rate was 95.4% in participants under 65 years of age, whereas it was 91.8% in those aged 65 years and over. There was no significant difference in the mean age between those with positive and negative antibody results (p > 0.05). Although antibody levels were lower older people, smokers, and those with chronic diseases, this difference was not statistically significant (p > 0.05). Seropositivity developed following the administration of two doses of CoronaVac-Sinovac vaccines. IgG antibody levels were lower in older adults, smokers, and those with chronic diseases, although not to a statistically significant extent. Further studies are needed to better understand the reasons for the different immunological responses to COVID-19.Keywords
This publication has 18 references indexed in Scilit:
- Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccineDiabetes/Metabolism Research and Reviews, 2021
- Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 VaccinationClinical Infectious Diseases, 2021
- Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational studyThe Lancet, 2021
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trialTrials, 2020
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2Emerging Infectious Diseases, 2020
- Estimating the effects of non-pharmaceutical interventions on COVID-19 in EuropeNature, 2020
- The COVID-19 vaccine development landscapeNature Reviews Drug Discovery, 2020
- Likert scales, levels of measurement and the “laws” of statisticsAdvances in Health Sciences Education, 2010